All news articles for December 2021

© GettyImages/Martin Barraud

4D Pharma sees positive data from early stage asthma trial

By Jane Byrne

Live biotherapeutic product (LBP) developer, 4D Pharma, which has been NASDAQ listed since March this year, has announced positive topline results for the first part of its Phase I/II trial of an LBP strain for the treatment of asthma.

Pic:getty/andrewbrookes

Biogen halves price of Aduhelm in the US

By Rachel Arthur

As of January 1, 2022, Biogen will cut the price of its Alzheimer’s drug Aduhelm (aducanumab-avwa) in half: saying too many patients are not currently being offered the choice of the drug due to financial considerations.

© GettyImages/Monty Rakusen

Lonza and Doer Biologics in expression system license deal

By Jane Byrne

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.

Pic:getty/imagesbytangmingtung

Positive booster data for Sanofi/GSK COVID-19 vaccine

By Rachel Arthur

A single booster dose of Sanofi and GSK’s recombinant adjuvanted COVID-19 vaccine candidate delivered ‘consistently strong immune responses’, according to data released by the companies.

© GettyImages/Atstock Productions

SGS acquires live biotherapeutics focused CDMO

By Jane Byrne

SGS, the Swiss-based testing, inspection and certification company, has acquired Quay Pharma, a UK based pharmaceutical industry targeted contract development and manufacturing organization (CDMO).